Cefiderocol-Based versus Colistin-Based Regimens for Severe Carbapenem-Resistant Acinetobacter baumannii Infections: A Propensity Score-Weighted, Retrospective Cohort Study during the First Two Years of the COVID-19 Pandemic.
Mazzitelli MariaDario GregoriLolita SassetMarco TrevenzoliVincenzo ScaglioneSara Lo MenzoSerena MarinelloDaniele MengatoFrancesca VenturiniIvo TiberioPaolo NavalesiAnna Maria CattelanPublished in: Microorganisms (2023)
Cefiderocol treatment did not differ in terms of main outcomes and safety profile from colistin-based regimens. More prospective studies with a larger number of patients are required to confirm our results.